Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size and forecast to 2029

Ramkumarss20 Jun, 2023Business

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market was valued at USD 14 billion in 2022 and poised to reach USD 18.3 billion by 2029 growing at a CAGR of 5.0% during the forecast period 2022 to 2028. Dipeptidyl Peptidase IV (DPP-IV) inhibitors also known as gliptins are oral anti-diabetic drugs, commonly used in the treatment of Type-2 diabetes. Dipeptidyl Peptidase inhibitors act by inhibiting the degradation of incretins like GLP-1 by inhibition of the enzyme dipeptidyl peptidase IV.